Your browser is no longer supported. Please, upgrade your browser.
RGNX REGENXBIO Inc. daily Stock Chart
RGNX [NASD]
REGENXBIO Inc.
Index- P/E- EPS (ttm)-2.58 Insider Own0.60% Shs Outstand39.39M Perf Week-18.09%
Market Cap1.09B Forward P/E- EPS next Y-1.82 Insider Trans-41.71% Shs Float31.02M Perf Month-32.71%
Income-94.70M PEG- EPS next Q-0.87 Inst Own92.80% Short Float14.06% Perf Quarter-29.06%
Sales35.20M P/S31.05 EPS this Y-194.70% Inst Trans6.13% Short Ratio8.12 Perf Half Y-26.90%
Book/sh12.20 P/B2.27 EPS next Y-5.20% ROA-18.40% Target Price75.50 Perf Year-51.86%
Cash/sh7.52 P/C3.69 EPS next 5Y2.00% ROE-19.90% 52W Range20.03 - 59.95 Perf YTD-32.27%
Dividend- P/FCF- EPS past 5Y-68.50% ROI-32.50% 52W High-53.71% Beta1.06
Dividend %- Quick Ratio10.20 Sales past 5Y41.90% Gross Margin76.60% 52W Low38.54% ATR3.82
Employees257 Current Ratio10.20 Sales Q/Q-71.10% Oper. Margin- RSI (14)37.82 Volatility9.63% 14.13%
OptionableYes Debt/Eq0.00 EPS Q/Q-748.90% Profit Margin- Rel Volume0.82 Prev Close29.43
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 BMO Payout- Avg Volume537.29K Price27.75
Recom2.20 SMA20-9.12% SMA50-31.47% SMA200-32.08% Volume441,972 Change-5.71%
Aug-20-19Upgrade SVB Leerink Underperform → Mkt Perform $38 → $37
Jun-18-19Reiterated Chardan Capital Markets Buy $145 → $150
Jun-14-19Resumed Raymond James Outperform
Jun-05-19Reiterated Chardan Capital Markets Buy $127.50 → $145
Feb-25-19Upgrade Evercore ISI In-line → Outperform
Feb-05-19Upgrade Raymond James Outperform → Strong Buy $94
Dec-17-18Reiterated Chardan Capital Markets Buy $127.50
Nov-08-18Reiterated BofA/Merrill Neutral $76 → $84
Aug-08-18Reiterated Chardan Capital Markets Buy $130 → $127.50
Jul-23-18Downgrade BofA/Merrill Buy → Neutral
Jul-10-18Reiterated Chardan Capital Markets Buy $90 → $130
May-09-18Reiterated Barclays Overweight $38 → $48
Apr-09-18Reiterated Chardan Capital Markets Buy $85 → $90
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-13-18Initiated Mizuho Neutral $28
Nov-09-17Resumed Morgan Stanley Overweight $34
Nov-09-17Reiterated Chardan Capital Markets Buy $75 → $85
Oct-12-17Initiated Raymond James Outperform $39
Aug-17-17Initiated Evercore ISI Outperform $25
Aug-09-17Reiterated Chardan Capital Markets Buy $50 → $55
Mar-31-20 04:05PM  REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder GlobeNewswire
Mar-13-20 10:02AM  Should You Worry About REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Pay Cheque? Simply Wall St. +5.87%
09:34AM  These local companies took the biggest one-day hits on Wall Street on Thursday American City Business Journals
Mar-09-20 07:00AM  REGENXBIO to Present at the Barclays Global Healthcare Conference PR Newswire -10.24%
02:26AM  Edited Transcript of RGNX earnings conference call or presentation 26-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-02-20 08:45AM  These local companies have taken the biggest hits on Wall Street during current sell-off American City Business Journals
Feb-26-20 07:15PM  Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM  REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights PR Newswire
02:34PM  Novavax is working to advance a potential coronavirus vaccine. So are competitors. American City Business Journals
Feb-25-20 08:10AM  Coronavirus fears lead to Wall Street sell-off. Here are the D.C.-area companies hit the hardest. American City Business Journals -5.39%
Feb-19-20 12:31PM  Earnings Preview: Regenxbio (RGNX) Q4 Earnings Expected to Decline Zacks
Jan-29-20 07:00AM  REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium 2020 PR Newswire
Jan-28-20 01:12PM  How REGENXBIO Inc. (NASDAQ:RGNX) Can Impact Your Portfolio Volatility Simply Wall St.
Jan-10-20 10:08AM  Applied Genetic Stock Up on Favorable Eye Therapy Study Data Zacks
Jan-09-20 08:30PM  Edited Transcript of RGNX earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
07:00AM  REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update PR Newswire
Dec-19-19 04:22PM  These Hedge Funds Cashed Out Of Regenxbio Inc (RGNX) Too Early Insider Monkey
Dec-18-19 07:41AM  REGENXBIO Announces Interim Data from Phase I/II Trial of RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) PR Newswire
Dec-16-19 09:30AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-19 03:27PM  Top stock picks for 2020: Standout small companies MarketWatch
02:07PM  We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth Simply Wall St.
Dec-04-19 05:00AM  Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018 American City Business Journals
Nov-06-19 04:15PM  The FDA Paused This Biotech's Gene Therapy Study And Shares Tumbled Investor's Business Daily
Nov-05-19 06:25PM  Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights PR Newswire
Nov-02-19 12:00PM  What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One Investor's Business Daily
Oct-31-19 04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 07:05AM  Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector in AAV Gene Therapy Delivery GlobeNewswire -11.96%
Oct-29-19 07:00AM  REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights PR Newswire
Oct-25-19 12:49PM  Announcing: REGENXBIO (NASDAQ:RGNX) Stock Increased An Energizing 142% In The Last Three Years Simply Wall St. +5.48%
09:36AM  Is Regenxbio Inc (RGNX) Going to Burn These Hedge Funds? Insider Monkey
Oct-17-19 07:00AM  REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress PR Newswire
Oct-15-19 02:48PM  RegenxBio gets positive interim data for eye disease treatment American City Business Journals +8.36%
10:57AM  Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA Zacks
Oct-11-19 07:15PM  REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting PR Newswire
Oct-10-19 10:11AM  Wet AMD Space in Focus: New Drug Approvals & Key Advancements Zacks
Oct-06-19 05:15PM  The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck Benzinga
Oct-02-19 08:31AM  Ultragenyx Gets FDA Approval for Label Expansion of Crysvita Zacks
Oct-01-19 01:43PM  Biotech Roundtable: How to Invest in Medicines Future Barrons.com
Sep-30-19 07:00AM  REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference PR Newswire +6.75%
Sep-19-19 08:29AM  An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued Simply Wall St.
Sep-13-19 08:44AM  REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8% Zacks
Sep-09-19 12:58PM  This Rockville biotech has added another deal to its growth plan American City Business Journals
Sep-04-19 09:42AM  Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA Zacks
07:00AM  REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 PR Newswire
Aug-28-19 04:05PM  REGENXBIO to Present at Upcoming Investor Conferences PR Newswire
01:31PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Aug-27-19 07:00AM  REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October PR Newswire
Aug-23-19 07:36AM  Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues Zacks
Aug-21-19 07:15PM  Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares GuruFocus.com
Aug-12-19 04:33AM  Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-19 10:14AM  Regenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 06:15PM  Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM  REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD PR Newswire
Aug-06-19 02:20PM  Is REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jul-31-19 07:07AM  REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector PR Newswire
Jul-30-19 04:05PM  REGENXBIO To Host Conference Call on August 7 to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights PR Newswire
Jul-24-19 04:10PM  REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases PR Newswire
04:05PM  REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases PR Newswire
Jul-23-19 06:15PM  Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $742,350 of Shares GuruFocus.com
Jul-02-19 08:41AM  Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock? Zacks -8.14%
Jun-19-19 09:07PM  Heres What Hedge Funds Think About Regenxbio Inc (RGNX) Insider Monkey
Jun-11-19 07:00AM  REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference PR Newswire
Jun-03-19 02:32PM  Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-28-19 01:47PM  FDA approves most expensive gene therapy ever and here is its connection to Penn American City Business Journals +7.19%
11:25AM  REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4% Zacks
May-24-19 07:46PM  Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio Motley Fool +7.44%
01:14PM  REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform PR Newswire
May-15-19 07:00AM  REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies PR Newswire
May-08-19 07:00AM  REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire -8.52%
May-07-19 09:24PM  Regenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript Motley Fool
06:36PM  Regenxbio: 1Q Earnings Snapshot Associated Press
04:05PM  REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD PR Newswire
May-02-19 12:40PM  Is Regenxbio Inc (RGNX) A Good Stock To Buy? Insider Monkey
Apr-30-19 07:00AM  REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights PR Newswire
Apr-22-19 04:15PM  A Second Baby Died In A Gene Therapy Study Slugging This Biotech Stock Investor's Business Daily -7.80%
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
01:22PM  Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain? Simply Wall St.
Apr-17-19 07:00AM  REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer PR Newswire
Apr-15-19 04:05PM  REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting PR Newswire
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
Apr-03-19 08:16AM  3 Small-Cap Biotech Stocks to Watch Now Motley Fool
Mar-26-19 07:15AM  New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-08-19 10:40AM  Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next? Motley Fool
Mar-06-19 07:00AM  REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire -5.56%
Mar-05-19 08:44AM  REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher Zacks
Mar-04-19 10:43AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool +5.12%
Mar-01-19 09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com
09:07PM  Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 09:41PM  Regenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights PR Newswire
09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
Feb-26-19 08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-20-19 07:00AM  REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights PR Newswire
Feb-14-19 07:00AM  REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists PR Newswire
Feb-04-19 07:20AM  Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-31-19 07:00AM  REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease PR Newswire
Jan-29-19 12:36PM  Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Jan-21-19 02:14PM  REGENXBIO Inc. (NASDAQ:RGNX): Time For A Financial Health Check Simply Wall St.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vasista VittalChief Financial OfficerMar 31Option Exercise0.8510,0008,500220,215Apr 02 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 11Option Exercise22.006,633145,92616,512Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 11Sale50.4912,564634,4113,948Feb 12 04:27 PM
HAYDEN DONALD J JRDirectorFeb 10Option Exercise0.8524,80021,08024,800Feb 12 04:22 PM
Vasista VittalChief Financial OfficerFeb 10Option Exercise13.093,00039,270225,021Feb 12 04:24 PM
Simpson CurranSVP, Product Development & CTOFeb 10Option Exercise27.1031,660858,09854,308Feb 12 04:27 PM
Vasista VittalChief Financial OfficerFeb 10Sale50.0714,806741,352210,215Feb 12 04:24 PM
HAYDEN DONALD J JRDirectorFeb 10Sale50.1124,8001,242,7280Feb 12 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 10Sale50.2244,4292,231,2249,879Feb 12 04:27 PM
HAYDEN DONALD J JRDirectorFeb 05Option Exercise0.852,0001,7002,000Feb 07 04:19 PM
Simpson CurranSVP, Product Development & CTOFeb 05Option Exercise18.085,13792,88628,285Feb 07 04:23 PM
Vasista VittalChief Financial OfficerFeb 05Sale50.0030015,000222,021Feb 07 04:21 PM
HAYDEN DONALD J JRDirectorFeb 05Sale50.002,000100,0000Feb 07 04:19 PM
Simpson CurranSVP, Product Development & CTOFeb 05Sale50.005,637281,85022,648Feb 07 04:23 PM
HAYDEN DONALD J JRDirectorJan 17Option Exercise0.853,2002,7203,200Jan 21 04:16 PM
Simpson CurranSVP, Product Development & CTOJan 17Option Exercise23.365,122119,66929,070Jan 21 04:18 PM
Simpson CurranSVP, Product Development & CTOJan 17Sale50.005,922296,10023,148Jan 21 04:18 PM
Vasista VittalChief Financial OfficerJan 17Sale50.002,394119,700222,321Jan 21 04:17 PM
HAYDEN DONALD J JRDirectorJan 17Sale50.013,200160,0320Jan 21 04:16 PM
HAYDEN DONALD J JRDirectorJan 14Option Exercise0.8530,00025,50030,000Jan 16 04:18 PM
HAYDEN DONALD J JRDirectorJan 14Sale45.6030,0001,368,0000Jan 16 04:18 PM
Vasista VittalChief Financial OfficerJan 08Option Exercise13.093,00039,270232,215Jan 10 04:20 PM
Vasista VittalChief Financial OfficerJan 08Sale41.757,500313,152224,715Jan 10 04:20 PM
Simpson CurranSVP, Product Development & CTODec 09Sale43.7415,552680,24823,948Dec 11 04:24 PM
Mills Kenneth T.President and CEOSep 19Option Exercise0.855,0004,250251,000Sep 23 04:12 PM
Mills Kenneth T.President and CEOSep 19Sale39.7510,000397,497241,000Sep 23 04:12 PM
Christmas Patrick J.SVP, General CounselSep 12Option Exercise12.105,00060,5008,058Sep 16 04:24 PM
Christmas Patrick J.SVP, General CounselSep 12Sale42.005,486230,4122,572Sep 16 04:24 PM
Mills Kenneth T.President and CEOAug 19Option Exercise0.8515,00012,750261,000Aug 21 04:17 PM
Mills Kenneth T.President and CEOAug 19Sale37.5515,000563,243246,000Aug 21 04:17 PM
Mills Kenneth T.President and CEOJul 19Option Exercise0.8515,00012,750261,000Jul 23 04:33 PM
Christmas Patrick J.SVP, General CounselJul 19Option Exercise19.504,90095,5507,958Jul 22 04:29 PM
Mills Kenneth T.President and CEOJul 19Sale49.4915,000742,311246,000Jul 23 04:33 PM
Christmas Patrick J.SVP, General CounselJul 19Sale50.034,900245,1473,058Jul 22 04:29 PM
Christmas Patrick J.SVP, General CounselJul 18Option Exercise19.501001,9503,158Jul 22 04:29 PM
Christmas Patrick J.SVP, General CounselJul 18Sale50.001005,0003,058Jul 22 04:29 PM
Mills Kenneth T.President and CEOJun 19Option Exercise0.8515,00012,750261,000Jun 21 04:11 PM
Mills Kenneth T.President and CEOJun 19Sale52.5415,000788,088246,000Jun 21 04:11 PM
Christmas Patrick J.SVP, General CounselJun 18Option Exercise12.105,00060,5008,006Jun 20 04:20 PM
Christmas Patrick J.SVP, General CounselJun 18Sale52.995,000264,9653,006Jun 20 04:20 PM
Simpson CurranSVP, Product Development & CTOMay 28Option Exercise22.0018,000396,00057,500May 30 04:56 PM
Simpson CurranSVP, Product Development & CTOMay 28Sale50.0018,000900,00039,500May 30 04:56 PM
Mills Kenneth T.President and CEOMay 20Option Exercise0.8515,00012,750261,000May 22 04:18 PM
Mills Kenneth T.President and CEOMay 20Sale42.9915,000644,866246,000May 22 04:18 PM
Mills Kenneth T.President and CEOApr 22Option Exercise0.8515,00012,750261,000Apr 24 04:20 PM
Mills Kenneth T.President and CEOApr 22Sale50.4415,000756,566246,000Apr 24 04:20 PM
Christmas Patrick J.SVP, General CounselApr 18Option Exercise14.265,00071,2978,006Apr 22 04:17 PM
Christmas Patrick J.SVP, General CounselApr 18Sale53.235,000266,1613,006Apr 22 04:17 PM
Danos OlivierChief Scientific OfficerApr 15Option Exercise20.352,00040,7008,500Apr 17 04:19 PM
Danos OlivierChief Scientific OfficerApr 15Sale52.662,000105,3206,500Apr 17 04:19 PM